Researchers from The University of Texas at Dallas' Center for Vital Longevity (CVL) have released the full dataset from a ...

Cortechs.ai has announced a strategic partnership with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) aimed ...

Since Alzheimer's disease affects over 7 million people in the U.S., potentially doubling to 14 million by 2050, earlier ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Cortechs.ai, a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration with the ...

Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

Experts say the test could dramatically improve access to earlier, more accurate diagnoses, particularly for older Americans ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of the ...

The FDA cleared the first blood test on Friday to help diagnose Alzheimer's disease among older Americans already exhibiting ...